MedTrace Logo

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

NCT06697197 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 413

Last updated 2026-02-03

No results posted yet for this study

Summary

The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.

Conditions

Interventions

DRUG

BMS-986482

Specified dose on specified days

DRUG

Nivolumab and rHuPH20

Specified dose on specified days

DRUG

Nivolumab/relatlimab/rHuPH20

Specified dose on specified days

DRUG

Bevacizumab

Specified dose on specified days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-17
Primary Completion
2029-01-04
Completion
2029-01-05
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Denmark
  • France
  • Greece
  • Italy
  • Netherlands
  • Spain
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06697197 on ClinicalTrials.gov